CER Daily Newsfeed

A New Golden Age in Healthcare: The Early Report Card Shows Promise

(6/27, James P. Pinkerton, Jack Kalavritinos, RealClearHealth) comments “...Biden's Inflation Reduction Act—which should have been called the Inflation Expansion Act—slapped counterproductive price controls on many types of prescription drugs, with more to come. One result of this was a sharp drop-off in the number of clinical trials—the very stuff of future innovations for good health and life itself. Calculations from the National Pharmaceutical Council show that industry-sponsored trials fell by more than 38 percent.” Full

AAD Issues Recommendations for Four New Therapies for Adult Atopic Dermatitis

(6/27, Jennifer Fisher, MMSc, PA-C, Medscape) reports “The American Academy of Dermatology (AAD) recently issued a focused update to its guidelines on the management of atopic dermatitis (AD) in adults, strongly recommending four recently approved therapies: tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (in combination with topical therapy)...Despite the promising data, the authors acknowledged important limitations. Most trials were short-term (≤ 24 weeks), and the long-term safety, durability of response, and comparative effectiveness of these agents remain unknown.” Full

Video: The Role of Real-World Data in Advancing Value-Based Cancer Care: CK Wang, MD

(6/26, Giuliana Grossi, CK Wang, MD, The American Journal of Managed Care) “Real-world data is playing an increasingly critical role in advancing value-based care, particularly in oncology, where traditional clinical trials often fail to capture the full picture of patient experiences and care delivery. In this interview, CK Wang, MD, a hematologist-oncologist and the chief medical officer of COTA, discusses how real-world insights help identify disparities and gaps in cancer care, support more equitable outcomes, and empower stakeholders across the health care system.” View Video

Data Technology + RWD Are Positive for Rare Disease Treatment

(6/27, Jeff McDonald, MedCity News) comments “...To overcome hurdles within the rare disease space, using data intelligence technology and context embedded RWD can offer more insights while accelerating timelines and maintaining tighter control over costs. This is especially important in an era where time and funding are limited. Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development.” Full